Systemic Inflammation Induced by Lipopolysaccharide Increases Neointimal Formation After Balloon and Stent Injury in Rabbits

Haim D. Danenberg, MD; Frederick G.P. Welt, MD; Matthew Walker III, PhD; Philip Seifert, MS; Greg S. Toegel, BA; Elazer R. Edelman, MD, PhD

Background—Emerging data indicate that the inflammatory response after mechanical arterial injury correlates with the severity of neointimal hyperplasia in animal models and postangioplasty restenosis in humans. The present study was designed to examine whether a nonspecific stimulation of the innate immune system, induced in close temporal proximity to the vascular injury, would modulate the results of the procedure.

Methods and Results—Rabbits subjected to iliac artery balloon injury (balloon denudation with or without stent deployment) were injected twice with a bacterial lipopolysaccharide (LPS) (500 ng/rabbit) before and after surgery. The dose was chosen to be sufficient to induce systemic inflammation but not septic shock. A systemic marker of inflammation (serum interleukin-1β levels measured by ELISA) and monocytic stimulation (CD14 levels on monocytes measured by flow cytometry) were increased after LPS administration. Arterial macrophage infiltration at 7 days after injury was 1.7±1.2% of total cells in controls and 4.2±1.8% in LPS-treated rabbits (n=4, P<0.05). Morphometric analysis of the injured arteries 4 weeks after injury revealed significantly increased luminal stenosis (38±4.2% versus 23±2.6, mean±SEM; n=8, P<0.05) and neointima-to-media ratio (1.26±0.21 versus 0.66±0.09, P<0.05) in LPS-treated animals compared with controls. This effect was abolished by anti-CD14 Ab administration. Serum interleukin-1β levels and monocyte CD14 expression were significantly increased in correlation with the severity of intimal hyperplasia. LPS treatment increased neointimal area after stenting from 0.57±0.07 to 0.77±0.1 mm² and stenosis from 9±1% to 13±1.7% (n=5, P<0.05).

Conclusions—Nonspecific systemic stimulation of the innate immune system concurrently with arterial vascular injury facilitates neointimal formation, and conditions associated with increased inflammation may increase restenosis.

(Circulation. 2002;105:2917-2922.)

Key Words: balloon ■ stents ■ inflammation ■ leukocytes ■ restenosis

Intimal hyperplasia is a universal response of the arterial wall to mechanical injury, and it is a major cause of restenosis after percutaneous coronary interventions (PCIs). The multifactorial pathophysiology of restenosis remains as yet not entirely defined. Emerging experimental and clinical data indicate that inflammation is of major importance to the restenotic process.

Inflammatory cells are activated promptly after vascular injury1 and recruited to the site of injury.2-5 These cells are capable of releasing mediators that facilitate smooth muscle cell (SMC) migration and proliferation.6-8 In human studies, the severity of postangioplasty luminal loss has been found to correlate with activation of circulating leukocytes,9 and restenosis in patients undergoing directional atherectomy has been determined to be correlated with the percentage of macrophages in retrieved tissue at the time of angioplasty.10 Recently, polymorphism of the gene for interleukin (IL)-1 receptor antagonist, a protein that regulates inflammatory response, was found to be associated with reduced restenosis.11 Several antiinflammatory strategies have successfully limited neointimal hyperplasia after injury in animal models. Deactivation of circulating monocytes by IL-1012 and blocking leukocyte adhesion by use of an antibody (Ab) directed against the β2-integrin Mac-1 (CD11b/CD18)13 reduce neointimal formation after balloon injury and/or stent deployment in rabbits. Furthermore, vascular injury in Mac-1–deficient mice is associated with reduced leukocyte accumulation and reduced neointimal formation.14

The fundamental questions that arise are whether the stimulation of inflammation in vascular repair is specific or general and whether inflammation is localized to and controlled only at the site of injury alone or is responsive to systemic modulation. If injury is mediated by a specific inflammatory signal, then this specific pathway needs to be fully delineated and then targeted. Similarly, if the inflammatory process is local, then local therapy alone may suffice.
whereas systemic inflammation might require systemic therapy. Finally, a systemic nonspecific response would be sensitive to preexisting inflammation and other inflammatory events, whereas specific localized effects would not. The present study was designed to examine these issues. Rabbits subjected to iliac artery balloon injury, with or without stent deployment, were assigned to bacterial lipopolysaccharide (LPS) injection immediately before and 1 day after the procedure. We report that activation of the innate immune system by LPS is associated with an increased neointimal formation and luminal loss after vascular injury. Furthermore, this augmentation of neointimal growth is blocked by administration of a monoclonal Ab (mAb) directed against CD14.

Methods

Vascular Injury Model

Animal care and procedures were in accordance with the guidelines of the American Association for the Accreditation of Laboratory Animal Care and the National Institutes of Health. Male New Zealand White rabbits (Covance Products, Denver, Pa), 2.8 to 3.2 kg, were fed rabbit chow and water ad libitum. Under anesthesia with xylazine (5 mg/kg IM) and ketamine (35 mg/kg IM), the femoral arteries were exposed and ligated, and the iliac arteries were deenudated of endothelium by the intraluminal passage of a 3F arterial embolectomy catheter (Baxter) passed to the abdominal aorta and withdrawn in the inflated state 3 times. In 10 animals, a 9-mm metallic stent (NIR 7 cell, Medinol) mounted on a 3×15-mm-long balloon was implanted in the right iliac artery (15-second inflation at 8 atm) immediately after denudation, resulting in marked arterial overstretch (stent-to-artery ratio 1.1:1 to 1.2:1). Heparin (100 U/kg IV) was administered immediately after arteriotomy, and animals were treated with aspirin (0.07 mg/mL in drinking water). LPS (Escherichia coli 0127:B8, Sigma) was injected (500 ng/rabbit IV) immediately after denudation, resulting in marked arterial overstretch, whereas systemic inflammation might require systemic administration of a monoclonal Ab to balloon-injured animals did not change significantly after injection of LPS.

Determination of Monocyte Activation

CD14 Expression on Monocytes

CD14 is a protein essential for LPS-induced cellular activation. CD14 expression is increased in the activated monocyte. The activation status of monocytes was examined in triplicate by fluorescence-activated cell sorting (FACS) with fluorescent anti-CD14 antibodies. Anticoagulated blood was incubated for 30 minutes (200 μL, 4°C, in the dark) with mouse anti-human R-phycocerythrin–conjugated anti-CD14 (4 μL, Dako). FACS lysing solution (Becton Dickinson) was added for 15 minutes, and the residual cells were washed 3 times in FACS medium (PBS, 1% BSA, 0.02% sodium azide) (×1500 rpm, 5 minutes, 4°C). Cells were then suspended in 1 mL of FACS medium, and flow cytometry was performed within 1 hour (Becton Dickinson flow cytometer). Monocytes were identified according to their forward- and side-scattering properties as well as fluorescence.

Serum IL-1β Determination

IL-1β is a major product of monocytes, secreted in response to LPS. Serum was separated and stored at −70°C until further analysis. After it was thawed, IL-1β levels were measured in triplicate with a commercial ELISA kit (Biosource International).

Statistical Analysis

All data are presented as mean±SEM. Comparisons between treatment groups used an unpaired, 2-tailed t test. Values of P<0.05 were considered significant.

Results

Effect of LPS on Balloon Injury–Induced Intimal Hyperplasia

Morphometric analysis of balloon-injured arteries at 28 days after injury revealed concentric neointimal hyperplasia in both control and LPS-treated animals (Figure 1, A–D). Neointimal area was increased by 48% in LPS-treated rabbits. Neointima-to-media (N/M) ratio and luminal stenosis were increased significantly, by 91% and 65%, respectively (Figure 1E). Luminal area was reduced by 29%. Total arterial area and medial area were reduced insignificantly in LPS-treated animals, by 12% and 20%, respectively. Arteries not injured by balloons revealed no histological difference between control and LPS-treated animals (data not shown). Administration of anti-CD14 Ab to balloon-injured animals did not affect neointimal growth. When it was administered to LPS-stimulated rabbits, the increase in neointimal growth was not significantly different from control levels (Figure 1E). Heart rate, blood pressure, and respiration were not changed significantly after injection of LPS.

Effect of LPS on Stent-Induced Intimal Hyperplasia

Not unexpectedly, intimal hyperplasia in control arteries implanted with NIR stents was relatively modest, with an
intimal area of 0.57±0.07 mm² and stenosis of 9±1%. LPS treatment increased neointimal area significantly, by 35%, to 0.77±0.1 mm² and stenosis by 44%, to 13±1.7% (Figure 2; n=5, P<0.05 for both intimal area and stenosis). Medial area was unchanged and luminal area was reduced insignificantly by LPS (5.81±0.6 and 5.2±0.33 mm², control and LPS-treated, respectively).

**Immunohistochemical Staining for Leukocytes**

Macrophage infiltration into the injured arterial wall was recorded at 7 days after injury. LPS administration resulted in an increase in RAM11-positive cells in the vessel wall from 1.7±1.2% of total cells to 4.2±1.8% (Figure 3; n=4, P<0.05).

**CD14 Expression on Blood Monocytes**

CD14 expression on circulating monocytes was increased significantly in LPS-treated animals compared with injured controls. At 6 hours after vascular injury, there was a 120±25% increase in CD14 expression after LPS treatment, whereas no change was recorded in controls (n=4; Figure 4). Expression at 24 hours was increased by 64% and 30% in LPS-treated animals and controls, respectively. Anti-CD14 Ab administration was associated with complete disappear-

---

(Images and figures are not transcribed but are referenced for context.)
ance of CD14-positive monocytes at 24 hours after injection (data not shown).

Serum IL-1β

IL-1β levels in serum were increased at 6 hours after injury in both control and LPS-treated rabbits. At 24 hours after injury, IL-1β levels were increased by 79% over baseline levels in LPS-treated animals (Figure 5A) and reduced by 25% in controls (from 530±163 to 950±53 pg/mL and 474±273 to 352±162 pg/mL, LPS and control, respectively, mean±SD; n=3 in each group; \( P=0.016 \)). To examine the predictive value of early nonspecific stimulation of the innate immune system on late intimal hyperplasia, the serum IL-1β change over baseline at 24 hours after injury was correlated with the N/M ratio at 30 days. A strong positive correlation was demonstrated (\( r^2=0.88 \)), with the highest increase in IL-1β associated with the maximal N/M ratio (Figure 5B).

Discussion

Inflammation is essential to neointimal formation after experimental vascular injury and restenosis after percutaneous clinical vascular intervention. Leukocytes are central promoters and constituents of intimal proliferation, and vascular injury of many forms evokes a marked inflammatory state that correlates with subsequent restenosis. What has not been clear until now is whether the exacerbation of vascular injury by inflammation is a local phenomenon restricted to the site of injury alone or whether global and systemic inflammation, even of a nonspecific and preexisting nature, might contribute as well. It is as yet undefined whether systemic inflammatory mediators, such as C-reactive protein, that correlate with restenosis are markers of increased risk or are causative in and of themselves. The present study demonstrates that LPS administration leads to increased neointimal growth, probably via systemic, nonspecific activation of leukocytes. Correlation was found between systemic inflammation, as measured by blood IL-1β levels, and late intimal growth.

Monocytes, macrophages, and neutrophils are immediately activated in response to infection and injury, including vascular mechanical injury. Neutrophils infiltrate an injured vessel wall rapidly, followed by monocytes. Adaptive T lymphocyte–mediated immune responses are probably not involved in neointimal proliferation after balloon dilatation. Thrombin-activated platelets and increased monocyte chemotactic protein-1 expression by injured endothelial cells are among the stimuli that activate monocytes after vascular injury. Macrophages express numerous growth factors, cytokines, and enzymes that facilitate SMC migration and proliferation. Systemic modulation of macrophage function inhibits neointimal formation by various modalities, including IL-10 deactivation of monocytes and mAb blockade of Mac-1, a \( \beta_2 \)-integrin expressed on leukocytes.

LPS administration stimulates blood monocytes, which increases production and secretion of growth factors. When administered with vascular balloon injury, LPS activated blood monocytes, increased systemic production of IL-1β, and increased local vascular infiltration of macrophages, all associated with increased intimal hyperplasia. Even in an injury model in which the hyperplastic response is minimal, ie, after implantation of clinically available stents, LPS increased both inflammation and injury. Both systemic secretion of inflammatory mediators and/or increased arrival of highly activated monocytes to the site of injury may explain increased intimal growth. The early increase in serum IL-1β and its correlation with further intimal growth may indicate that systemic secretion is associated with the late growth effect, whereas the increased macrophage infiltration sup-

---

**Figure 4.** Monocyte activation after balloon injury. Line graph of a representative flow cytometry analysis for CD14 expression on peripheral blood monocytes in control and LPS-treated rabbits. MFA indicates median fluorescent activity.

**Figure 5.** Serum IL-1β after injury and relation to intimal hyperplasia. A, Serum IL-1β levels after vascular injury in control and LPS-treated rabbits (n=3, \( P<0.05 \)). B, Correlation between IL-1β serum level increase at 24 hours and N/M ratio at 28 days in control and LPS-treated animals.
ports a local effect. The 2 mechanisms, however, may be interrelated. The proinflammatory cytokine IL-1β increases adhesion of leukocytes to SMCs through increased expression of intercellular adhesion molecule-1 and CD 44 and increases IL-6 production by SMCs. Thus, IL-1β may indirectly affect SMC activation and proliferation and matrix formation, positively correlating with postinjury neointimal formation.

LPS affects cells involved in healing of vascular injury other than CD14-positive leukocytes. It can cause endothelial vacuolization and desquamation at much higher doses than those used in this study and increases intercellular adhesion molecule-1 expression on these cells. LPS induces the expression of procoagulant tissue factor in epithelial cells and activates vascular SMCs probably through soluble CD14 receptors. In the present study, blockade of these receptors by mAbs abolished the enhanced formation of neointima after LPS. Thus, additional mechanisms other than the activation of CD14-positive monocytes may underlie the effect observed in this study. Interestingly, total blockade of CD14 in animals not treated with LPS had no effect on neointimal formation (Figure 1E). Thus, the inflammatory response that can affect vascular healing is secondary to several different stimuli, of which CD14-activation is but one.

Although “nonspecific” antiinflammatory drugs effectively reduce neointimal formation and restenosis after experimental vascular injury in a wide variety of models, their effects have not been reproduced in randomized clinical trials. The discrepancy and lack of clinical efficacy may result from inadequate dosing; from the increased inflammation associated with the surgery performed in animals before arteriotomy, unlike the “minimal” percutaneous procedure performed in humans; or from the large burden of inflammatory cells already present in human atherosclerotic lesions and the inability of the antiinflammatory regimen to block the acute-phase innate response. In 2 clinical trials in which systemic glucocorticoids failed to affect restenosis, methylprednisolone was injected <24 hours before PCI with or without continuous steroid therapy. This mode of administration may initially stimulate macrophages, and it may be that the rapid macrophage trafficking to the injured vessel requires a more immediate and macrophage-specific systemic antiinflammatory protocol.

The association of a nonspecific inflammatory response and increased neointimal formation may have relevance for certain clinical situations associated with higher rates of adverse outcome, such as end-stage renal failure and dialysis, both of which involve constant activation and phenotypic modulation of monocytes that may affect their activity when recruited to the site of injury.

Systemic inflammation caused by infection, unrelated to the vascular injury, can modify the healing process. Cytophagocytosis of the infected cells may reduce neointimal formation after balloon injury, probably via systemic inflammatory changes. On the basis of the present study, we may assume that the inflammatory response that affects vascular healing is not pathogen specific.

Clinical or subclinical bacteremia may accompany up to 8% of PCIs. Although completely asymptomatic and subclinical, such bacteremia may stimulate the innate immune system, which in turn affects the long-term results of PCI. Thus, special caution regarding the prevention and detection of infection is warranted.

In conclusion, nonspecific systemic stimulation of the innate immune system concurrently with arterial injury is associated with increased neointimal formation, creating a cycle of injury and inflammation, which contribute to and stimulate each other. These findings add to our understanding of how the outcome of PCIs may differ, the lack of correlation between experimental and clinical studies, and how systemic inflammation should be considered and minimized whenever possible in the setting of intracoronary interventions.

References
Systemic Inflammation Induced by Lipopolysaccharide Increases Neointimal Formation After Balloon and Stent Injury in Rabbits

Haim D. Danenberg, Frederick G. P. Welt, Matthew Walker III, Philip Seifert, Greg S. Toegel and Elazer R. Edelman

_Circulation_. 2002;105:2917-2922; originally published online May 20, 2002; doi: 10.1161/01.CIR.0000018168.15904.BB

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/105/24/2917

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/